Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. reports biotechnology developments centered on emavusertib (CA-4948), an orally available small-molecule IRAK4 and FLT3 inhibitor. Company updates focus on oncology programs in lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia, including clinical data presentations, combination approaches with BTK inhibitors, and studies involving venetoclax and azacitidine.
Recurring Curis news also covers quarterly financial and operating results, conference-call updates, capital actions such as private placements, and security-structure matters involving preferred stock and warrants. The company’s public updates combine clinical-program progress with financing, governance and operating disclosures typical of a development-stage biotechnology issuer.
Curis, Inc. (NASDAQ: CRIS) will release its first quarter 2024 financial results on May 7, 2024, followed by a conference call. The company is focused on developing emavusertib (CA-4948), an IRAK4 inhibitor. Investors can access the call via phone or the company's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.